Comparison of efficacy and safety between liposome-paclitaxel injection plus carboplatin and paclitaxel plus carboplatin as first line treatment in advanced non-small cell lung cancer / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
; (6): 305-308, 2014.
Artigo
em Inglês
| WPRIM (Pacífico Ocidental)
| ID: wpr-329829
Biblioteca responsável:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To compare the efficacy and safety between liposome-paclitaxel plus carboplatin (LPC) and paclitaxel plus carboplatin (PC) as first-line treatment for advanced non-small cell lung cancer (NSCLC).</p><p><b>METHODS</b>Totally 54 chemotherapy-naive NSCLC patients were equally and randomly assigned into LPC group and PC group. Liposome-paclitaxel was injected on D1 at a dosage of 175 mg/m(2); the same dose and administration with paclitaxel injection in the PC group for a maximum of 2 cycles. The efficacy and adverse reactions after 2 cycles of chemotherapy were compared between these two groups.</p><p><b>RESULTS</b>The overall response rate (CR+PR) was 44.4% in the LPC group and 33.3% in the PC group after 2 cycles of chemotherapy respectively (P=0.577). In the LPC group and PC group, the incidences of myelodepression was 81.5% and 63.0%, respectively (P=0.080), gastrointestinal toxicity was 96.3% and 77.8% respectively (P=0.100), and allergic reactions was 0 and 11.1%, respectively (P=0.000). The median time to progression was 6 months and 5 months, respectively (P=0.420).</p><p><b>CONCLUSION</b>LPC group has the same efficacy with PC group and less adverse reactions than PC group.</p>
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Carboplatina
/
Resultado do Tratamento
/
Paclitaxel
/
Carcinoma Pulmonar de Células não Pequenas
/
Tratamento Farmacológico
/
Lipossomos
/
Neoplasias Pulmonares
Limite:
Adulto
/
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Acta Academiae Medicinae Sinicae
Ano de publicação:
2014
Tipo de documento:
Artigo